About

Management Team

 

 

Steven B. Bernitz Senior Vice President, Corporate Development

Mr. Bernitz joined Synta as Senior Vice President, Corporate Development in December 2013. Most recently, Mr Bernitz was a General Partner and Head of the BioPharma Practice at Extera Partners, a business development advisory firm. At Extera, he led numerous business development and strategy initiatives for development stage companies and their investors, principally in oncology, autoimmune and orphan diseases. Prior to joining Extera in 2010, Mr. Bernitz was Chief Business Officer at Concert Pharmaceuticals where he led Concert’s $1 billion deal with GlaxoSmithKline, and prior to Concert he was Senior Vice President, Business and Product Development at Coley Pharmaceutical Group, where he led numerous transactions including Coley’s $600 million oncology deal with Pfizer. Mr. Bernitz has also been CEO of Histogenics and Organogenesis, both cell therapy companies, and earlier in his career was with Merck Vaccines and McKinsey & Co. Mr. Bernitz earned his MBA from the J.L. Kellogg Graduate School of Management at Northwestern University where he was an Austin Scholar, and his B.S. summa cum laude from Tufts University where he was elected to Phi Beta Kappa. [Back to Top]

Safi R. Bahcall, Ph.D.

Arthur J. McMahon Senior Vice President, People Operations

Before joining Synta in January 2007, Mr. McMahon served as Senior Director of Human Resources for Cabot Corporation, a publicly traded specialty chemical company. From 1995 to 2001, Mr. McMahon was Vice President of Human Resources for Osprey Systems, Inc., a privately owned software and information technology services company. Mr. McMahon’s past experience in the field of human resources also includes positions with Broadway and Seymour, Inc., Wang Laboratories, Inc. and Raytheon Company. Mr. McMahon earned his B.S. from North Carolina State University and his J.D. from Suffolk University Law School. [Back to Top]

Arthur J. McMahon

Vojo Vukovic, M.D., Ph.D. Senior Vice President, Chief Medical Officer

Dr. Vukovic joined Synta as Vice President, Clinical Research in January 2009. Dr. Vukovic has over 17 years experience in oncology drug development. Prior to Synta, he was Global Medical Lead for Sutent® and axitinib in a number of cancer indications at Pfizer. Prior to Pfizer, he served in key medical and regulatory roles at Aventis Pasteur, Ortho Biotech, ILEX Oncology, and BioNumerik Pharmaceuticals. Over the course of his career, Dr. Vukovic has been responsible for over 100 Phase 1 to Phase 4 clinical studies in cancer indications including melanoma, tumors of the lung, pancreas, breast, colorectal, ovarian, brain, as well as NHL and certain leukemias. Prior to his industry career, Dr. Vukovic was a post-doctoral fellow at the Ontario Cancer Institute, Toronto in Ontario and Institute for Cell Biology in Essen, Germany where he conducted basic and translational research in solid tumor microenvironments and oxidative stress. Dr. Vukovic received his Ph.D. and M.Sc. degrees from the University of Toronto and his M.D. degree from the University of Sarajevo, Bosnia and Herzegovina. [Back to Top]

Vojo Vukovic, M.D., Ph.D.

Suresh R. Babu, Ph.D. Vice President, Drug Product Development

Before joining Synta in January 2006, Dr. Babu was employed at Pfizer Global R&D with responsibility for discovery formulation, preformulation, and formulation development. Prior to Pfizer, Dr. Babu worked for Johnson & Johnson identifying and implementing new technologies for drug delivery. Dr. Babu has extensive pharmaceutical industry experience in the areas of preformulation, enabling dosage forms, drug delivery, and the development of immediate and controlled release dosage forms. Dr. Babu has several years of teaching experience in Pharmaceutical Sciences. He earned his B.S. in Pharmacy (India) and Ph.D. in Pharmaceutics at the University of Connecticut, Storrs, Connecticut. Dr. Babu is a member of the Advisory Board of the School of Pharmacy at the University of Connecticut, Storrs, Connecticut. [Back to Top]

Suresh R. Babu, Ph.D.

Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer

Before joining Synta in March 2004, Mr. Ehrlich was Vice President-Finance and Administration and Chief Financial Officer at Argentys Corporation. Previously, Mr. Ehrlich was Vice President-Finance and Administration and Chief Financial Officer at Dyax Corp. and OraVax Inc. (now Acambis) and Director of Finance at Vertex Pharmaceuticals, Inc. He had financial responsibility for the initial public offerings of OraVax and Vertex. Previously, Mr. Ehrlich was a Senior Audit Manager for PricewaterhouseCoopers. Mr. Ehrlich holds a B.A. in Biology from Drew University and an M.B.A. from Rutgers University. [Back to Top]

Keith S. Ehrlich, C.P.A.

Iman El-Hariry, M.D., Ph.D. Vice President, Clinical Research

Dr. El-Hariry is an oncologist with 13 years global pharmaceutical oncology development experience. Dr. El-Hariry joined Synta in December 2010 from Astellas Pharma where she served as the company’s first Global Head of Oncology. Prior to Astellas, Dr. El-Hariry served in key clinical development roles at GlaxoSmithKline (GSK), where she oversaw over 50 Phase 1 through Phase 4 clinical trials, led multiple European and U.S. regulatory agency submissions resulting in successful product approvals, and initiated and led a broad network of academic and medical community collaborations in support of GSK oncology drug candidates. Dr. El-Hariry holds an M.D. (Hons) from Alexandria Medical School, Alexandria, Egypt and a Ph.D. in Clinical Oncology from the Imperial College of Science and Medicine, London, UK. [Back to Top]

Iman El-Hariry, M.D., Ph.D.

Christine Redmond, M.P.H. Vice President, Operations and Program Management

Ms. Redmond joined Synta in July 2012. Ms. Redmond has held key clinical development roles at Molecular Insight Pharmaceuticals, Dyax Corp., Acorda Therapeutics and Mannkind where she managed the execution of over 40 clinical trials, including several phase 3 programs that led to NDA and BLA approvals. Most recently, she served as Senior Program Director at Lantheus Medical Imaging where she was responsible for the strategic global execution of a large Phase 3 program for a diagnostic imaging agent. Ms. Redmond holds an M.P.H. in Epidemiology from the University of Massachusetts, Amherst, School of Public Health and Health Sciences and a B.A. in Biology from Wheaton College. [Back to Top]

Christine Redmond, M.P.H.

Wendy E. Rieder, Esq. Vice President, Intellectual Property and Legal Affairs, General Counsel

Before joining Synta in December 2002, Ms. Rieder served as the co-founder, COO and VP, Business Development and Intellectual Property of Microbiotix, Inc., a privately-held biotechnology company developing small-molecule anti-infectives. She is a registered patent attorney with experience in all aspects of business and intellectual property law relating to private and public companies in the pharmaceutical and biotechnology industries. Ms. Rieder was also the VP, Business Development and Intellectual Property at CereMedix, Inc. and LipoGenics, Inc., a patent attorney at Boehringer Ingelheim Pharmaceuticals, and a patent agent at Fish & Neave. Ms. Rieder holds an M.S. in Organic Chemistry from Columbia University and a J.D. from Fordham University. [Back to Top]

Wendy E. Rieder, Esq.

Dvorit Samid, Ph.D. Vice President, Medical Affairs

Dr. Dvorit Samid joined Synta as Vice President, Medical Affairs, in March 2012. Dr. Samid has three decades of oncology research and drug development experience including clinical development, launch and life-cycle management of drugs in lung cancer (Erbitux), breast cancer (Abraxane, Xeloda), and colorectal cancer (Xeloda). Her career spans academia (Associate Professor - University of Virginia Medical School), government (Section Chief – Differentiation Control, National Cancer Institute/National Institutes of Health Division of Cancer Treatment) and pharmaceutical industry (Head of Medical Affairs at Roche, ImClone and others). Dr. Samid holds a Ph.D. in Cell Biology from Catholic University of America in Washington, D.C., completed graduate studies in Biology at Technion Institute in Haifa, Israel and holds a B.Sc. in Microbiology from Hebrew University in Jerusalem, Israel. Dr. Samid has authored over 80 publications in oncology and holds 19 patents. [Back to Top]

Dvorit Samid, Ph.D.

Andrew J. Sonderfan, Ph.D., DABT Vice President, Drug Disposition and Preclinical Safety

Before joining Synta in December 2006, Dr. Sonderfan spent five years at Enanta Pharmaceuticals, Inc., during which time he served as Senior Director, Toxicology and Safety Pharmacology. From 2000 to 2001, Dr. Sonderfan was the Director of Toxicology and Product Safety at BioChem Pharma (today, Shire Pharmaceutical Development Inc.). Dr. Sonderfan began his industry career at Syntex, Inc. as Nonclinical Leader, Palonosetron Program. Dr. Sonderfan earned his B.S. in Toxicology from the Philadelphia College of Pharmacy and Science (today, the University of the Sciences in Philadelphia) and his Ph.D. in Toxicology from the University of Kansas Medical Center. [Back to Top]

Andrew J. Sonderfan, Ph.D., DABT

Thomas Wilson Vice President, Quality Assurance

Mr. Wilson joined Synta in November 2012 with over 14 years leadership experience in quality assurance, analytic support, and chemistry, manufacturing, and controls (CMC) including responsibility for six NDA submissions and numerous INDs. Previously, Mr. Wilson established the quality departments and systems for Sepracor (from 1998 to 2006, now Sunovion), Orexigen Therapeutics (from 2008 to 2011), and Euthymics Bioscience (from 2011 to 2012). He also provided regulatory and CMC consulting while at Analytical Bio-Chemistry Laboratories from 2006 to 2008, and held quality and analytical positions at Mallinckrodt (now Covidien) and Granutec, a former subsidiary of Novopharm Ltd. Mr. Wilson received a B.Sc from Truman State University. [Back to Top]

Thomas Wilson

Ilker Yalcin, Ph.D., Vice President, Biostatistics and Data Management

Prior to joining Synta in May 2011, Dr. Ilker Yalcin was Research Advisor/Group Leader of the Global Oncology Business Unit at Eli Lilly and Company where he was responsible for helping design innovative clinical trials, leading development of multiple oncology compounds, performing pharmacogenetics analyses and managing a team of statisticians. Over his 15 year tenure at Eli Lilly, Dr. Yalcin held increasingly senior leadership positions including Director – Statistics, where he managed the statistical team in Endocrine, Oncology, Women’s Health, Urology, Reproductive Medicine, Cardiovascular and Critical Care in Lilly USA. Prior to joining Eli Lilly, Dr. Yalcin served as Biostatistician/Epidemiologist for the World Health Organization, Division of Mental Health in Geneva, Switzerland. Dr. Yalcin received his Ph.D. in Statistics from Iowa State University, and his M.B.A. from Indiana University, Kelly School of Business. [Back to Top]

Ilker Yalcin, Ph.D., M.B.A.